Kev muag khoom ncaj qha los ntawm Tuam Tshoj Hoobkas CAS 1006376-62-0(1R,2R)-2-(3,4-difluorophenyl)cyclopropane carboxaMide Kub Muag Tshuag

Ticagrelor yog ib qho tshuaj tiv thaiv kab mob hauv qhov ncauj, nws lub npe Asmeskas yog Brilinta, thiab nws lub npe European yog Brilique. Ticagrelor yog ib qho kev thim rov qab platelet adenosine diphosphate (ADP) receptor antagonist tsim los tiv thaiv platelets los ntawm kev ua ke thiab tsim cov ntshav txhaws uas tuaj yeem ua rau lub plawv nres thiab mob stroke. Hauv Tebchaws Meskas, ticagrelor tau pom zoo thawj zaug los ntawm FDA thaum Lub Xya Hli 2011 rau kev kho mob ntawm cov neeg laus cov neeg mob uas muaj tus mob coronary syndrome (ACS). Cov ntaub ntawv kho mob qhia tau hais tias ticagrelor muaj txiaj ntsig zoo dua li clopidogrel hauv kev txo cov hlab plawv tuag tsawg kawg 12 lub hlis tom qab kev tshwm sim ACS. Tsis tas li ntawd, ticagrelorChemicalbook kuj txo qhov tshwm sim ntawm stent thrombosis (ST) hauv cov neeg mob uas tau txais stents los kho ACS. Thaum Lub Rau Hli 2020, AstraZeneca tshaj tawm tias US Food and Drug Administration (FDA) tau pom zoo cov tshuaj tiv thaiv kab mob Brilinta (ticagrelor) rau cov neeg mob uas muaj kev pheej hmoo siab mob plawv (CAD) kom txo tau qhov kev pheej hmoo ntawm thawj lub plawv nres. los yog pheej hmoo mob stroke. Thaum Lub Kaum Ib Hlis 2020, AstraZeneca tshaj tawm tias US Food and Drug Administration (FDA) tau pom zoo ib qho kev qhia tshiab rau cov tshuaj tiv thaiv kab mob Brilinta (ticagrelor), ua ke nrog tshuaj aspirin, rau kev kho mob ntawm ischemia. Hauv cov neeg mob hemorrhagic stroke lossis high-risk transient ischemic attack (TIA), nws txo qhov kev pheej hmoo ntawm mob stroke.